drugset

drugset / Trial / NCT01017120

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

NCT01017120 ↗

Phase 3 Completed 742 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.

Timeline

Start: 2009-10-01
Primary completion: 2010-11-01
Completion: 2010-11-09

Publications

Background Feldman SR, Werner CP, Alio Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr;12(4):438-46.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tazarotene	Small molecule	0.1 %	Topical

Indications